Paediatric Respiratory Reviews
Volume 10, Issue 4 , Pages 192-198 , December 2009

Pneumocystis pneumonia in children

  • Vasilios Pyrgos

      Affiliations

    • Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    • Section of Infectious Diseases, Washington Hospital Center, Washington, DC, USA
    • ,
  • Shmuel Shoham

      Affiliations

    • Section of Infectious Diseases, Washington Hospital Center, Washington, DC, USA
    • ,
  • Emmanuel Roilides

      Affiliations

    • Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    • 3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece
    • ,
  • Thomas J. Walsh

      Affiliations

    • Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    • Corresponding Author InformationCorresponding author. Senior Investigator, Chief, Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, CRC 1-5750, 10 Center Drive, Bethesda, MD 20892, USA. Tel.: +301 402 0023; fax: +301 480 2308.

References 

  1. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988;334:519–522
  2. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292–300
  3. Wakefield AE, Stewart TJ, Moxon ER, Marsh K, Hopkin JM. Infection with Pneumocystis carinii is prevalent in healthy Gambian children. Trans R Soc Trop Med Hyg. 1990;84:800–802
  4. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61:35–41
  5. Olsson M, Lidman C, Latouche S, et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol. 1998;36:1737–1740
  6. Medrano FJ, Montes-Cano M, Conde M, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis. 2005;11:245–250
  7. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–2498
  8. Vargas SL, Ponce CA, Gigliotti F, et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol. 2000;38:1536–1538
  9. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis. 1982;145:842–848
  10. Cheung YF, Chan CF, Lee CW, Lau YL. An outbreak of Pneumocystis carinii pneumonia in children with malignancy. J Paediatr Child Health. 1994;30:173–175
  11. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?. Clin Infect Dis. 2007;44:1143–1149
  12. Dutz W, Post C, Vessal K, Kohout K. Endemic infantile Pneumocystis carinii infection: the Shiraz study. Natl Cancer Inst Monogr. 1976;43:31–40
  13. Larsen HH, von Linstow ML, Lundgren B, Høgh B, Westh H, Lundgren JD. Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis. 2007;13:66–72
  14. Stagno S, Pifer LL, Hughes WT, Brasfield DM, Tiller RE. Pneumocystis carinii pneumonitis in young immunocompetent infants. Pediatrics. 1980;66:56–62
  15. Vargas SL, Ponce CA, Hughes WT, et al. Association of primary Pneumocystis carinii infection and sudden infant death syndrome. Clin Infect Dis. 1999;29:1489–1493
  16. Vargas SL, Ponce CA, Galvez P, et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J. 2007;26:81–83
  17. Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis. 1995;172:595–598
  18. Latouche S, Poirot JL, Bernard C, Roux P. Study of internal transcribed spacer and mitochondrial large-subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus-infected patients during one or several episodes of pneumonia. J Clin Microbiol. 1997;35:1687–1690
  19. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713–1720
  20. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana. Pediatr Infect Dis J. 2003;22:43–47
  21. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MR. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA. 1993;270:470–473
  22. Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53(RR-14):1–92
  23. Branten AJ, Beckers PJ, Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrol Dial Transplant. 1995;10:1194–1197
  24. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13
  25. Arend SM, Kroon FP, van’t Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med. 1995;155:2436–2441
  26. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963
  27. Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. 1993;94:216–219
  28. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis. 2007;39:589–595
  29. Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004–2009
  30. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34:1098–1107
  31. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knustson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49:135–142
  32. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22:610–616
  33. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891–3897
  34. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22:920–925
  35. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 1995;151(3 Pt 1):795–799
  36. Godeau B, Coutant-Perronne V, Le Thi Huong T, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246–251
  37. Kalyoncu U, Karadag O, Akdogan A, et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis. 2007;39:475–478
  38. Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis. 2004;10:436–437
  39. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481–1484
  40. BenMustapha-Darghouth I, Trabelsi S, Largueche B, Bejaoui M, Dellagi K, Barbouche MR. Prevalence of Pneumocystis jiroveci pneumonia in Tunisian primary immunodeficient patients. Arch Pediatr. 2007;14:20–23
  41. Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82:373–384
  42. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103:456–464
  43. Deerojanawong J, Chang AB, Eng PA, Robertson CF, Kemp AS. Pulmonary diseases in children with severe combined immune deficiency and DiGeorge syndrome. Pediatr Pulmonol. 1997;24:324–330
  44. Limper AH, Martin WJ. Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment. J Clin Invest. 1990;85:391–396
  45. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest. 1997;99:2110–2117
  46. Linke MJ, Harris CE, Korfhagen TR, et al. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. J Infect Dis. 2001;183:943–952
  47. Neese LW, Standing JE, Olsen EJ, Castro M, Limper AH. Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-alpha in response to Pneumocystis carinii. J Immunol. 1994;152:4549–4556
  48. Hidalgo HA, Helmke RJ, German VF, Mangos JA. Pneumocystis carinii induces an oxidative burst in alveolar macrophages. Infect Immun. 1992;60:1–7
  49. Steele C, Marrero L, Swain S, et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med. 2003;198:1677–1688
  50. Tachado SD, Zhang J, Zhu J, Patel N, Cushion M, Koziel H. Pneumocystis-mediated IL-8 release by macrophages requires coexpression of mannose receptors and TLR2. J Leukoc Biol. 2007;81:205–211
  51. Ezekowitz RA, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature. 1991;351:155–158
  52. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest. 1998;102:1332–1344
  53. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah C. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161–165
  54. Garvy BA, Qureshi MH. Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment. J Immunol. 2000;165:6480–6486
  55. Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest. 1999;103:1151–1158
  56. Beck JM, Warnock ML, Cutis JL, et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol. 1991;5:186–197
  57. Shellito J, Suzara VV, Blumenfeld W, Beck JM, Sterger HJ, Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest. 1990;85:1686–1693
  58. McAllister F, Steele C, Zheng M, et al. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol. 2004;172:1132–1138
  59. McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK, et al. T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. J Immunol. 2006;177:6215–6226
  60. Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. J Immunol. 2003;171:1423–1430
  61. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol. 2006;176:6147–6154
  62. Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest. 1988;81:1666–1668
  63. Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev. 1997;10:401–418
  64. Walzer PD, Smulian AG. Pneumocystis species. In:  Mandell GL,  Bennet JE,  Dolin R editor. Principles, Practice of Infectious, Diseases. Philadelphia: Elsevier Churchill Livingstone; 2005;p. 3080–3094
  65. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–671
  66. Masur H. Pneumocystosis. In:  Dolin R,  Masur R,  Saag MS editor. AIDS Therapy. Philadelphia: Churchill Livingstone; 2003;p. 403–418
  67. Barry SM, Lipman MC, Deery AR, Johnson MA, Janossy G. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med. 2002;3:207–211
  68. Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 2001;164:847–851
  69. Selwyn PA, Pumerantz AS, Durante A, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. Aids. 1998;12:885–893
  70. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol. 1997;169:967–975
  71. Boiselle PM, Crans CA, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol. 1999;172:1301–1309
  72. DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987;91:323–327
  73. Williams AJ, Duong T, McNally LM, et al. Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. Aids. 2001;15:335–339
  74. Bakeera-Kitaka S, Musoke P, Downing R, Tumwine JK. Pneumocystis carinii in children with severe pneumonia at Mulago Hospital, Uganda. Ann Trop Paediatr. 2004;24:227–235
  75. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(Suppl 2):S416–422
  76. Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J. 2002;20:982–989
  77. Ognibene FP, Shelhamer J, Gill V, et al. The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis. 1984;129:929–932
  78. Golden JA, Hollander H, Stulbarg MS, Gamsu G. Bronchoalveolar lavage as the exclusive diagnostic modality for Pneumocystis carinii pneumonia. A prospective study among patients with acquired immunodeficiency syndrome. Chest. 1986;90:18–22
  79. Broaddus C, Dake MD, Stulbarg MS, et al. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;102:747–752
  80. Stokes DC, Shenep JL, Parhm D, Bozeman PM, Marienchek W, Mackert PW. Role of flexible bronchoscopy in the diagnosis of pulmonary infiltrates in pediatric patients with cancer. J Pediatr. 1989;115:561–567
  81. Huang L, Morris A, Limper AH, Beck JM. ATS Pneumocystis Workshop Participants. An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc. 2006;3:655–664
  82. Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis. 2004;189:1679–1683
  83. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest. 1995;108:415–418
  84. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;131:1173–1180
  85. Kawagishi N, Miyagi S, Satoh K, Akamatsu Y, Sekiguchi S, Satomi S. Usefulness of beta-D glucan in diagnosing Pneumocystis carinii pneumonia and monitoring its treatment in a living-donor liver-transplant recipient. J Hepatobiliary Pancreat Surg. 2007;14:308–311
  86. Marty FM, Koo S, Bryar J, Baden LR. (1->3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med. 2007;147:70–72
  87. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med. 1987;165:926–931
  88. Huang L, Crothers K, Atzori C, et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis. 2004;10:1721–1728
  89. Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1980;92:762–769
  90. Rieder MJ, King SM, Read S. Adverse reactions to trimethoprim-sulfamethoxazole among children with human immunodeficiency virus infection. Pediatr Infect Dis J. 1997;16:1028–1031
  91. Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis. 2004;10:1760–1765
  92. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004;48:4301–4305
  93. Miller TL, Winter HS, Luginbuhl LM, Orav EJ, McIntosh K. Pancreatitis in pediatric human immunodeficiency virus infection. J Pediatr. 1992;120(2 Pt 1):223–227
  94. Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care. 1995;18:47–55
  95. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996;124:792–802
  96. Sin DD, Shafran SD. Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:477–481
  97. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521–1527
  98. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med. 1994;121:174–180
  99. Sleasman JW, et al. Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia. Am J Dis Child. 1993;147:30–34
  100. Bye MR, Cairns-Bazarian AM, Ewig JM. Markedly reduced mortality associated with corticosteroid therapy of Pneumocystis carinii pneumonia in children with acquired immunodeficiency syndrome. Arch Pediatr Adolesc Med. 1994;148:638–641
  101. Delclaux C, Hemenway C, Klein AS, Barrett DJ. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670–672
  102. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215–1224
  103. Simonds RJ, Lindegren ML, Thomas P, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. N Engl J Med. 1995;332:786–790
  104. Kaplan JE, Masur H, Holmes K. Guidelines for the prevention of opportunistic infections among HIV-infected persons - 2002. MMWR Recomm Rep. 2002;51:1–52
  105. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005;115:e488–494
  106. Esposito S, Bojanin K, Porta A, Cesati L, Gualtieri L, Pincipi N. Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24:1117–1120
  107. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis. 2001;33:1397–1405
  108. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17:770–782
  109. Gigliotti F, Wright TW. Immunopathogenesis of Pneumocystis carinii pneumonia. Expert Rev Mol Med. 2005;7:1–16

PII: S1526-0542(09)00048-7

doi: 10.1016/j.prrv.2009.06.010

Paediatric Respiratory Reviews
Volume 10, Issue 4 , Pages 192-198 , December 2009

Article Tools